

ANNUAL

RESEARCH MEETING

TODAY'S RESEARCH DRIVING TOMORROW'S OUTCOMES

Exploring a Universal Lead Screening Requirement: A California Case Study

Erin Shigekawa, MPH California Health Benefits Review Program University of California, Berkeley

Co-Authors

Sara McMenamin, PhD, MPH, UC San Diego

Sarah Hiller, MPIA, UC San Diego

 Riti Shimkhada, PhD, MPH, UCLA Center for Health Policy Research





Overview

- The California Health Benefits Review Program
- State Activity in the Social Determinants of Health
- California Case Study: Lead Screening Bill
- Challenges and Considerations





The California Health Benefits Review Program

 Independent and objective resource that provides evidence-based analyses for the California Legislature

- Analyzes current bills at the request of the Legislature
 - 3 areas: Medical effectiveness, cost and use, public health

Timely, rigorous analyses produced in 60 days or less





The CHBRP Team

- Team model:
 - Central staff at UC Berkeley
 - Faculty and staff task force from several UC campuses
 - Actuaries
 - Medical librarians
- Advisors and reviewers:
 - Content experts
 - National Advisory Council





State Activity in the Social Determinants of Health

- Medicaid waivers and pilot programs
- State task forces (e.g., Health in All Policies)
- Legislation
 - Screening and testing policy
 - Coverage of services





California Case Study: Lead Screening Bill

No level of lead in the body is known to be safe.

- Common sources of lead include:
 - Lead-based paint (pre-1978);
 - Lead contaminated soil and dust;
 - Some foods, cosmetics, and dishware with leaded glaze.



California Case Study: Lead Screening Bill

As introduced, Assembly Bill 1316 would require:

- State-regulated insurance to provide coverage for blood lead level testing of all children 6-72 months (rather than only those "at-risk")
 - Targeted → universal
- Essentially changes standard of care
- Appropriate case management if lead poisoning identified (via Department of Public Health)







Medical Effectiveness Findings

Individual Level:

- Damage is irreversible
- Possible to minimize further exposure



Population Level:

 Insufficient evidence that a universal screening approach is more effective than a targeted approach







Public Health Impacts

Individual Level:

 4,800 additional children with elevated blood lead levels would be identified in year one; mitigation



Population Level:

- Potential for future identification of lead exposure "hot spots"
 - → lead abatement, prevention on community level
 - → requires action by other state agencies, stakeholders







Challenges and Considerations

- Complexities for policy makers
 - Evidence, resources, potential harms of exposure, intervention
- Impacting social determinants through legislation
- By definition, issue is broader than health care delivery
- May require coordination of multiple state agencies





California Health Benefits Review Program www.chbrp.org



@CHBRP_at_UC



